Cervix Uteri Carcinoma in Situ disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CRV002 MIFTS: 45	Cervix Uteri Carcinoma in Situ Categories: Cancer diseases, Rare diseases, Reproductive diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Cervix Uteri Carcinoma in Situ

MalaCards integrated aliases for Cervix Uteri Carcinoma in Situ:

Name: Cervix Uteri Carcinoma in Situ ¹¹ ¹⁴ ³³

Carcinoma in Situ of Uterine Cervix ¹¹ ⁷¹

Cervical Intraepithelial Neoplasia ⁴³ ⁷¹

Carcinoma in Situ of Cervix ¹¹ ³³

Cervical Intraepithelial Neoplasia Grade Iii with Severe Dysplasia ¹¹

Cervix Intraepithelial Neoplasia Grade 3 Ajcc V7 ⁷¹

Squamous Intraepithelial Neoplasia, Grade Iii ¹¹

Cin Iii - Carcinoma in Situ of Cervix ¹¹

Severe Dysplasia of the Cervix Uteri ¹¹

Cin Iii - Severe Dyskaryosis ¹¹

Carcinoma of Cervix Stage 0 ¹¹

Severe Dysplasia of Cervix ¹¹

Cervix Ca in Situ ¹¹

Cin Iii ¹¹

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Neoplasms

In situ neoplasms

Carcinoma in situ of cervix uteri

Carcinoma in situ: Cervix, unspecified

ICD11: ³³

Neoplasms

In situ neoplasms, except of lymphoid, haematopoietic, central nervous system or related tissues

Carcinoma in situ of cervix uteri

Carcinoma in situ of cervix uteri, unspecified

Other specified carcinoma in situ of cervix uteri

External Ids:

Disease Ontology ¹¹ DOID:8991

ICD9CM ³⁴ 233.1

MeSH ⁴³ D018290

SNOMED-CT ⁶⁸ 92564006

ICD10 ³¹ D06 D06.9

ICD11 ³³ 1072810807 1072810807/other 1072810807/unspecified

UMLS ⁷¹ C0206708 C0851140 C2987516

Sources

Summaries for Cervix Uteri Carcinoma in Situ

Disease Ontology: ¹¹ An uterus carcinoma in situ that is located in the uterine cervix.

MalaCards based summary: Cervix Uteri Carcinoma in Situ, also known as carcinoma in situ of uterine cervix, is related to cervicitis and human papillomavirus infectious disease. An important gene associated with Cervix Uteri Carcinoma in Situ is CADM1 (Cell Adhesion Molecule 1), and among its related pathways/superpathways are 22q11.2 copy number variation syndrome and TP53 network. The drugs Aluminum hydroxide and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include uterine cervix, cervix and uterus, and related phenotype is homeostasis/metabolism.

Sources

Related Diseases for Cervix Uteri Carcinoma in Situ

Diseases in the Rare Cancer of Cervix Uteri family:

Cervix Uteri Carcinoma in Situ

Diseases related to Cervix Uteri Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 265)

#	Related Disease	Score	Top Affiliating Genes
1	cervicitis	31.2	ZNF582 SERPIND1 GP6 GP5 CDKN2A
2	human papillomavirus infectious disease	31.2	TP53 GP5 FHIT CDKN2A
3	cervical intraepithelial neoplasia	31.1	KRT17 FHIT CDKN2A
4	vulva cancer	30.7	ZNF582 TP53 GP5 CDKN2A
5	cervical adenocarcinoma	30.7	TP53 MAPK8IP1 INSM1 CDKN2A
6	anus cancer	30.6	ZNF582 TP53 GP6 GP5 CDKN2A
7	cervix carcinoma	30.5	TP53 PTPRN MAPK8IP1 INSM1 GP5 CDKN2A
8	adenosquamous carcinoma	30.5	PTPRN MAPK8IP1 INSM1 FHIT
9	cervical carcinosarcoma	30.4	MAPK8IP1 GP5
10	cervical incompetence	30.4	PTPRN MAPK8IP1 INSM1
11	suppressor of tumorigenicity 3	30.4	TP53 FHIT CDKN2A
12	keratinizing squamous cell carcinoma	30.3	TP53 CDKN2A
13	cervical squamous cell carcinoma	30.3	TP53 KRT17 FHIT CDKN2A
14	oropharynx cancer	30.3	TP53 GP5 CDKN2A
15	chronic cervicitis	30.2	ZNF582 TP53 SERPIND1 PAX1 INSM1 GP6
16	epidermodysplasia verruciformis 1	30.2	TP53 GP6 GP5 CDKN2A
17	anus disease	30.2	ZNF582 TP53 GP5 CDKN2A
18	endocervical adenocarcinoma	30.2	TP53 MAPK8IP1 INSM1 CDKN2A
19	vaginal cancer	30.1	TP53 MAPK8IP1 INSM1 GP5 CDKN2A
20	anogenital venereal wart	30.1	TP53 GP6 GP5 CDKN2A
21	vulva squamous cell carcinoma	30.0	ZNF582 TP53 GP5 CDKN2A
22	cervical cancer	29.9	TP53 RUBCNL FHIT CDKN2A CADM1
23	adenocarcinoma in situ	29.8	TP53 PTPRN MAPK8IP1 INSM1 GP5 CDKN2A
24	common cold	10.8
25	chlamydia	10.8
26	viral infectious disease	10.7
27	bacterial vaginosis	10.6
28	vaginal discharge	10.6
29	rhabdomyosarcoma 2	10.5
30	retinoblastoma	10.5
31	vaginitis	10.5
32	hypoascorbemia	10.5
33	human immunodeficiency virus type 1	10.5
34	oculodentodigital dysplasia	10.4
35	preterm premature rupture of the membranes	10.4
36	47 xxx syndrome	10.4
37	ceroid lipofuscinosis, neuronal, 5	10.4
38	herpes simplex	10.4
39	factor vii deficiency	10.4
40	progressive non-infectious anterior vertebral fusion	10.4
41	polyploidy	10.4
42	early invasive cervical adenocarcinoma	10.3	INSM1 CDKN2A
43	photoparoxysmal response 1	10.3
44	ectopic pregnancy	10.3
45	turner syndrome	10.3
46	syphilis	10.3
47	48,xyyy	10.3
48	cervical adenoid basal carcinoma	10.3	MAPK8IP1 KRT17
49	b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)	10.3	TP53 CDKN2A
50	endometrial squamous cell carcinoma	10.3	TP53 CDKN2A

Comorbidity relations with Cervix Uteri Carcinoma in Situ via Phenotypic Disease Network (PDN):

Adenomyosis

Myofibroma

Graphical network of the top 20 diseases related to Cervix Uteri Carcinoma in Situ:

Sources

Symptoms & Phenotypes for Cervix Uteri Carcinoma in Situ

MGI Mouse Phenotypes related to Cervix Uteri Carcinoma in Situ:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	9.47	CDKN2A FHIT GP5 GP6 INSM1 KRT17

Sources

Drugs & Therapeutics for Cervix Uteri Carcinoma in Situ

Drugs for Cervix Uteri Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 151)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Aluminum hydroxide

Approved, Investigational

Phase 4

21645-51-2

Racepinephrine

Approved, Vet_approved

Phase 4

51-43-4, 329-65-7

838 5816

Bupivacaine

Approved, Investigational

Phase 4

2180-92-9, 38396-39-3

2474

Monophosphoryl lipid A

Phase 4

Epinephryl borate

Phase 4

Neurotransmitter Agents

Phase 4

Bronchodilator Agents

Phase 4

Adrenergic beta-Agonists

Phase 4

Adrenergic alpha-Agonists

Phase 4

Adrenergic Agonists

Phase 4

Anti-Asthmatic Agents

Phase 4

Adrenergic Agents

Phase 4

Vasoconstrictor Agents

Phase 4

Anesthetics, Local

Phase 4

Respiratory System Agents

Phase 4

Mydriatics

Phase 4

Sympathomimetics

Phase 4

Vaccines

Phase 4

Fluorouracil

Approved

Phase 3

51-21-8

3385

Aluminum sulfate

Approved

Phase 3

10043-01-3

Lidocaine

Approved, Vet_approved

Phase 3

137-58-6

3676

Eugenol

Approved

Phase 3

97-53-0

3314

Imiquimod

Approved, Investigational

Phase 3

99011-02-6

57469

Acetic acid

Approved

Phase 3

64-19-7

176

Fenretinide

Investigational

Phase 3

65646-68-6

5288209

3,3'-diindolylmethane

Investigational

Phase 3

1968-05-4

3071

Zuretinol acetate

Investigational

Phase 3

127-47-9, 29584-22-3

10245972

Antimetabolites

Phase 3

Immunosuppressive Agents

Phase 3

Anesthetics

Phase 3

Antiviral Agents

Phase 3

Retinamide

Phase 3

Protective Agents

Phase 3

Immunoglobulins

Phase 3

Antibodies

Phase 3

Hemostatics

Phase 3

Olive

Phase 3

Anti-Arrhythmia Agents

Phase 3

Sodium Channel Blockers

Phase 3

Diuretics, Potassium Sparing

Phase 3

Adjuvants, Immunologic

Phase 3

interferons

Phase 3

Immunologic Factors

Phase 3

Raspberry

Approved

Phase 2

Aluminium phosphate

Approved, Investigational

Phase 2

7784-30-7

Eflornithine

Approved, Withdrawn

Phase 2

70052-12-9

3009

Celecoxib

Approved, Investigational

Phase 2

169590-42-5

2662

Masoprocol

Approved, Investigational

Phase 1, Phase 2

500-38-9, 27686-84-6

71398

Levoleucovorin

Approved, Experimental, Investigational

Phase 2

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Pemetrexed

Approved, Investigational

Phase 2

150399-23-8, 137281-23-3

60843 446556 135565230

Interventional clinical trials:

(show top 50) (show all 302)

#	Name	Status	NCT ID	Phase	Drugs
1	A Randomized Controlled Trial Evaluating the Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) in Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer	Unknown status	NCT02629510	Phase 4	Tachosil
2	Can Mindfulness Meditation Limit the Progression and/or Increase the Remission of Cervical Dysplasia?	Unknown status	NCT00842738	Phase 4
3	Management of Cervical Intraepithelial Neoplasia Grade 2	Completed	NCT00733109	Phase 4
4	HPV Vaccination Impact on Cervical Cancer Screening Program: FASTER-Tlalpan Study in Mexico	Completed	NCT03105856	Phase 4
5	Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization During General Anesthesia: A Randomized Controlled Double Blinded Study	Completed	NCT02368054	Phase 4	Bupivacaine;Adrenaline
6	Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study	Completed	NCT03629886	Phase 4
7	A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women	Completed	NCT01544478	Phase 4
8	A Study to Assess the Immunogenicity Consistency of Three Consecutive Batches of Commercial-scale of Recombinant Human Papillomavirus(HPV) Bivalent Vaccine (Escherichia Coli) in Healthy Female Subjects Aged 9-14 Years	Completed	NCT05426148	Phase 4
9	Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease	Completed	NCT01034358	Phase 4
10	Effectiveness of Cervical Screening in HPV Vaccinated Women - A Randomized Trial	Active, not recruiting	NCT02149030	Phase 4
11	Prospective Observational Immunogenicity Trial of Gardasil-9 HPV Vaccine in People Living With Adequately Managed HIV	Not yet recruiting	NCT05266898	Phase 4
12	A Randomized, Single Blinded Trial to Evaluate the Efficacy of Imiquimod in Women With Residual/Recurrent Cervical Intraepithelial Neoplasia (CIN) After Previous Treatment	Unknown status	NCT02669459	Phase 3	Imiquimod
13	DNA Methylation Testing for the Screening of Uterine Cervical Lesion: A Multicenter, Prospective Cohort Study	Unknown status	NCT04646954	Phase 3
14	A Phase III Double Blinded, Randomized Controlled Study to Evaluate Efficacy of Protection Against HPV-16 and 18 Related Diseases, Immunogenicity and Safety of HPV-16/18 Vaccine in Healthy Females Aged 18-30 Years	Unknown status	NCT02733068	Phase 3
15	The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical	Unknown status	NCT03366493	Phase 3
16	Randomized Controlled Trial of Vaginal Self Sampling for Human Papillomavirus to Increase Cervical Cancer Screening Participation	Unknown status	NCT01095198	Phase 2, Phase 3
17	A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica.	Completed	NCT00128661	Phase 3
18	A Randomized Double-Blind Study of N-(4-hydroxyphenyl) Retinamide (4-HPR) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3	Completed	NCT00003075	Phase 3	Fenretinide
19	Topical Imiquimod in Treating Patients With Grade 2/3 Cervical Intraepithelial Neoplasia	Completed	NCT00941252	Phase 2, Phase 3	Topical imiquimod therapy
20	Long-term Extension Study of the Efficacy of the 580299 Vaccine in the Prevention of HPV-16 and/or HPV-18 Associated Cervical Intraepithelial Neoplasia (CIN) in Japanese Women Vaccinated in the Primary Vaccination Study NCT00316693	Completed	NCT00929526	Phase 3
21	Diindolylmethane (DIM) Dietary Supplementation: A Nonsurgical Treatment for Cervical Intraepithelial Neoplasia (CIN)	Completed	NCT00212381	Phase 3	di indolylmethane (DIM)
22	Immunogenicity and Safety Study of a Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years	Completed	NCT02562508	Phase 3
23	Large Loop Excision of Transformation Zone Cone Versus Straight Wire Excision of Transformation Zone : Histopathological Analysis of Excision Margins	Completed	NCT01929993	Phase 3
24	Phase 3 Randomized Controlled Trial of Non-inferiority of Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix	Completed	NCT02130323	Phase 2, Phase 3	Imiquimod
25	Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects From the HPV-058 Study	Completed	NCT03355820	Phase 3
26	Randomized Trial of Immediate Treatment vs. Colposcopic Follow-up for Biopsy-Proven CIN 1	Completed	NCT00156026	Phase 3
27	A Study of Two Cone Biopsy Techniques For Women With Cervical Pre-Invasive Disease. LLETZ Cone and SWETZ.	Completed	NCT00995020	Phase 3
28	Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS)	Completed	NCT01131312	Phase 3
29	A Long-term, Open, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV-16/18 L1/AS04 Vaccine in Healthy Female Subjects Vaccinated Either Pre- or Post-menarche in the Primary Study	Completed	NCT00337818	Phase 3
30	A Long-term, Open Follow-up of the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Vaccinated in Study HPV-013	Completed	NCT00316706	Phase 3
31	Single Visit Cervical Cancer Prevention Program	Completed	NCT00237562	Phase 3
32	A Phase III Multicenter, Randomized, Double-Blind, Placebo(Hepatitis E Vaccine)Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant(E.Coli)Human Papillomavirus Bivalent Vaccine in Healthy Women	Completed	NCT01735006	Phase 3
33	Randomized Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL	Completed	NCT03721978	Phase 3
34	Human Papillomavirus DNA Testing Using Self-collected Samples for Cervical Cancer Screening: an Alternative Strategy for Unscreened Women?	Completed	NCT01014026	Phase 3
35	Efficiency of AV2 Antiviral Drug in the Treatment of Human Papillomavirus-associated Precancerous Lesions of the Uterine Cervix: a Randomized Clinical Trial in Kinshasa, Democratic Republic of the Congo	Completed	NCT02346227	Phase 3	AV2;Placebo
36	A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women	Completed	NCT00000758	Phase 3	Fluorouracil
37	A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix	Completed	NCT03185013	Phase 3
38	A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Amolimogene (ZYC101a) in the Treatment of High-Grade Cervical Intraepithelial Lesions (CIN 2/3) of the Uterine Cervix	Completed	NCT00264732	Phase 2, Phase 3	Amolimogene
39	Forced Versus Spray Coagulation in Women Undergoing LLETZ-conization for Cervical Dysplasia: a Randomized Trial	Completed	NCT02330471	Phase 3
40	Lidocaine Spray Compared With Submucosal Injection in Reducing Pain During Loop Electrosurgical Excision Procedure: a Randomized Controlled Trial	Completed	NCT01505920	Phase 3
41	A Double Blind, Prospective, Randomized, Placebo Controlled, Multi-center Phase 3 Study to Evaluate Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL)	Active, not recruiting	NCT04484415	Phase 3
42	A Multicenter, Randomized, Double-Blind, Controlled (Bivalent Human Papillomavirus Vaccine (16,18 Type)(E. Coli)) Phase III Clinical Trial to Estimate Efficacy, Immunogenicity and Safty of the Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type) (E.Coli) in Healthy Women Aged 18 to 45 Years	Active, not recruiting	NCT04537156	Phase 3
43	A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years	Active, not recruiting	NCT03493542	Phase 3
44	A Randomised, Double-Blind, Placebo-Controlled, Phase III Study to Investigate the Efficacy of Presurgical 9-valent HPV Vaccination in Women Treated With LEEP for CIN 2+ and Initially Invasive Cervical Cancer.	Not yet recruiting	NCT03848039	Phase 3	Placebo
45	A Randomized Trial of Spectroscopy Versus Standard Care in Cervical Intraepithelial Neoplasia	Terminated	NCT00529464	Phase 3
46	ITIC2 Trial - Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia: Randomised Controlled, Non-inferiority Trial	Terminated	NCT01283763	Phase 3	Topical Imiquimod
47	TOPical Imiquimod Treatment of High-grade Cervical Intraepithelial Neoplasm: a Randomized Controlled Trial.	Terminated	NCT02329171	Phase 3	Imiquimod
48	A Phase 2 Trial to Evaluate the Efficacy and the Safety of Composite Gel Containing Black Raspberry Extract in Removing HPV From Patients With Cervical Intraepithelial Neoplasia(CIN) After Cervical Conization	Unknown status	NCT03745846	Phase 2
49	A Phase 2b Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)	Unknown status	NCT03274206	Phase 2	Placebo
50	A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 2 Clinical Trial to Evaluate the Efficacy and the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation(EP) in HPV Type 16 and/or 18 Positive Patients With Biopsy-proven Cervical Intraepithelial Neoplasia Grade 2(CIN2), Grade 2/3 (CIN2/3), Grade 3(CIN3)	Unknown status	NCT02596243	Phase 2

Search NIH Clinical Center for Cervix Uteri Carcinoma in Situ

Cochrane evidence based reviews: cervical intraepithelial neoplasia

Sources

Genetic Tests for Cervix Uteri Carcinoma in Situ

Sources

Anatomical Context for Cervix Uteri Carcinoma in Situ

Organs/tissues related to Cervix Uteri Carcinoma in Situ:

FMA: Uterine Cervix

MalaCards : Cervix, Uterus, Lymph Node, Nk Cells, Skin, Liver, T Cells

Sources

Publications for Cervix Uteri Carcinoma in Situ

Articles related to Cervix Uteri Carcinoma in Situ:

(show top 50) (show all 1045)

#	Title	Authors	PMID	Year
1	COVID-19 can lead to rapid progression of cervical intraepithelial neoplasia by dysregulating the immune system: A hypothesis. ⁶²	Becker S...Schild-Suhren M	36399874	2022
2	The Effect of Local Photodynamic Therapy with 5-aminolevulinic Acid in Treating Different Grades of Cervical Intraepithelial Neoplasia. ⁶²	Wang B...Zhang T	36368451	2022
3	HPV-genotyping versus conventional cervical cytology as a screening method to detect dysplastic cervical epithelial changes. ⁶²	Abbas M...Bettendorf O	36280748	2022
4	Analysis of the Results of Severe Intraepithelial Squamous Cell Lesions and Preinvasive Cervical Cancer Phototheranostics in Women of Reproductive Age. ⁶²	Gilyadova A...Reshetov I	36289783	2022
5	Concordance Rate of Colposcopy in Detecting Cervical Intraepithelial Lesions. ⁶²	Stuebs FA...Koch MC	36292125	2022
6	FT-IR combined with PSO-CNN algorithm for rapid screening of cervical tumors. ⁶²	Ma Y...Lv X	35868522	2022
7	Fermented Mangosteen (Garcinia mangostana L.) Supplementation in the Prevention of HPV-Induced Cervical Cancer: From Mechanisms to Clinical Outcomes. ⁶²	Kharaeva Z...Korkina L	36230630	2022
8	Immunohistochemical Study of p16INK4A, MIB-1 and CK17 in Pre-neoplastic and Neoplastic Epithelial Lesions of Cervix. ⁶²	Sahu PD...Battin SS	36448068	2022
9	Ocular Surface Squamous Neoplasia: A 12-Month Prospective Evaluation of Incidence in Waikato, New Zealand. ⁶²	Hossain RR...McKelvie J	35997381	2022
10	Evaluation of P16/Ki67 (CINtecPlus) and L1-capsid compared with HPV-genotyping in cervical cytology in women ≥35 years old focusing on patients with atypical squamous cells of undetermined significance. ⁶²	Abbas M...Bettendorf O	35720497	2022
11	Clinical Outcomes Associated with Endocervical Glandular Involvement in Patients with Cervical Intraepithelial Neoplasia III. ⁶²	Kim NR...So KA	35683385	2022
12	A Study of Cytokeratin-7 Expression and Clinicopathological Correlation in Dysplasia and Squamous Cell Carcinoma of the Cervix. ⁶²	Alva N N...Mysorker V	35345360	2022
13	Anal intraepithelial neoplasia screening in patients with human immunodeficiency virus infection. ⁶²	Fernandez Isart M...Gonzalez Argente FX	35285660	2022
14	Role of FoxP3-positive regulatory T-cells in regressive and progressive cervical dysplasia. ⁶²	Vattai A...Kolben T	34739585	2022
15	Pilot Study on the Effect of a Single Topical Application of Trichloroacetic Acid 85% on Normal Cervical Tissue. ⁶²	Nuranna L...Kekalih A	35668953	2022
16	Predictive Value of HPV E6/E7 mRNA Detection on the Outcome of Cervical LSIL. ⁶²	Cao L...Zhou D	35978997	2022
17	Cervical Pre-cancers: Biopsy and Immunohistochemistry. ⁶²	Kamal M	35928531	2022
18	Diagnosis of Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma by Cervical Biopsy under Colposcopy and Analysis of Factors Influencing. ⁶²	Wang Y...Mei H	35941961	2022
19	Phototheranostics of Cervical Neoplasms with Chlorin e6 Photosensitizer. ⁶²	Gilyadova A...Reshetov I	35008375	2022
20	Raman spectroscopic study of cervical precancerous lesions and cervical cancer. ⁶²	Wang J...Wu GH	33404885	2021
21	Prognostic impact of human papillomavirus infection on cervical dysplasia, cancer, and patient survival in Saudi Arabia: A 10-year retrospective analysis. ⁶²	Alhamlan F...Al-Ahdal M	34873934	2021
22	Coexistence of cervical endometriosis with premalignant and malignant gynecological pathologies: report on a series of 27 cases. ⁶²	Matalliotakis M...Goulielmos GN	34696701	2021
23	Preliminary study of the use of E6/E7mRNA detection in screening and triage management of HR-HPV infection during pregnancy. ⁶²	Yang YM...Liao QP	34733980	2021
24	Pathways of IFN-alpha Activation in Patients with Cervical Intraepithelial Neoplasia (CIN). ⁶²	Tirone NR...Michelin MA	34670303	2021
25	Clinical value of traditional laparotomy, extensive vaginal hysterectomy, and laparoscope-assisted vaginal hysterectomy in the treatment of patients with cervical intraepithelial neoplasia III. ⁶²	Xu Y...Lu L	35116556	2021
26	HPV-16/18 E6-induced APOBEC3B expression associates with proliferation of cervical cancer cells and hypomethylation of Cyclin D1. ⁶²	Fan Q...Wang YD	33631046	2021
27	Detection of HPV E6/E7 mRNA in the diagnosis of cervical cancer and precancerous lesions after kidney transplantation. ⁶²	Sun J...Guan Q	34306499	2021
28	The Help of HPV Integration Testing to Avoid the Misdiagnosis of a Patient with Stage Ia1 Cervical Cancer: A Case Report and Literature Review. ⁶²	Li J...Li W	34819743	2021
29	Correlation between multi-type human papillomavirus infections and viral loads and the cervical pathological grade. ⁶²	Li Y...Hao C	33020921	2021
30	IMMUNOHISTOCHEMICAL FEATURES OF THE EXPRESSION OF HUMAN PAPILLOMA VIRUS TYPE 16 IN PLEOMORPHIC ADENOMAS OF SALIVARY GLAND. ⁶²	Brodetskyi IS...Krotevych MS	33851578	2021
31	Increased PD-1 Level in Severe Cervical Injury Is Associated With the Rare Programmed Cell Death 1 (PDCD1) rs36084323 A Allele in a Dominant Model. ⁶²	da Silva MC...Lucena-Silva N	34290992	2021
32	Occult vaginal cancer recurrence after hysterectomy: a case report and literature review. ⁶²	Guo L...Hua K	33275476	2020
33	Co-infection between genotypes of the human papillomavirus and Chlamydia trachomatis in Mexican women. ⁶²	Escarcega-Tame MA...Guerra-Infante FM	32998641	2020
34	Cytological, Colposcopic and Pathohistological Correlation of HSIL and ASC H Findings. ⁶²	Jahic M...Hadzimehmedovic A	33424094	2020
35	A Study of Matrix Metalloproteinase-2 and Interleukin-18 in Preinvasive and Invasive Lesions of Cancer Cervix. ⁶²	Shukla S...Khattri S	33767565	2020
36	Ichthyosis uteri with dysplasia - A case report. ⁶²	Gargade CB...Deshpande AH	33154324	2020
37	A Cervical Smear Scare due to Monsel's Solution: A Case Report. ⁶²	Abdul Rahman MF...Yeo YC	34434339	2020
38	Role of molecular biomarker human papilloma virus (HPV) E6 oncoprotein in cervical cancer screening. ⁶²	Ara R...Goodman A	32680634	2020
39	Cisplatin treatment modulates Annexin A1 and inhibitor of differentiation to DNA 1 expression in cervical cancer cells. ⁶²	Prates J...Oliani SM	32768930	2020
40	HIF-1α, HIF-2α, and ProExC: diagnostic or prognostic relevance in conjunctival intraepithelial neoplasia? ⁶²	Nuessle S...Auw-Haedrich C	32458097	2020
41	The Burden of Cervical Cancer in Korea: A Population-Based Study. ⁶²	Kim J...Bae S	32872616	2020
42	Multiple sexual partners and vaginal microecological disorder are associated with HPV infection and cervical carcinoma development. ⁶²	Huang Y...Song B	32724435	2020
43	Study on the correlation between hTREC and HPV load and cervical CINI/II/III lesions and cervical cancer. ⁶²	He H...Cao L	32100923	2020
44	Regulation of LCoR and RIP140 expression in cervical intraepithelial neoplasia and correlation with CIN progression and dedifferentiation. ⁶²	Vogelsang TLR...Vattai A	32157438	2020
45	Expression level of miRNA-210-3p in cervical cancer and its prognostic potential. ⁶²	Shao MX...Zhong YY	32633346	2020
46	Adjuvant VACcination against HPV in surgical treatment of Cervical Intra-epithelial Neoplasia (VACCIN study) a study protocol for a randomised controlled trial. ⁶²	van de Laar RLO...Van Beekhuizen HJ	32517663	2020
47	Relevance research between the expression of p16INK4a , Notch1, and hTERC genes: The development of HPV16-positive cervical cancer. ⁶²	Huo W...Bai H	31976596	2020
48	p16/Ki-67 dual-stained cytology used for triage in cervical cancer opportunistic screening. ⁶²	Han Q...Wang Y	32410798	2020
49	Cervical carcinoma risk associate with genetic polymorphisms of NEIL2 gene in Chinese population and its significance as predictive biomarker. ⁶²	Ye F...Chen H	32198476	2020
50	CIN III and cervical SCC with negative oncogenic HPV PCR: A case series. ⁶²	Sturrock S...Jobling T	31724153	2020

Sources

Genes for Cervix Uteri Carcinoma in Situ

Genes related to Cervix Uteri Carcinoma in Situ (0 elite genes):

(show all 22)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CADM1	Cell Adhesion Molecule 1	Protein Coding	13.52	DISEASES inferred ¹⁴ GeneCards inferred via : Summaries (show sections)
2	LCOR	Ligand Dependent Nuclear Receptor Corepressor	Protein Coding	7.11	DISEASES inferred ¹⁴ ¹⁴
3	SERPIND1	Serpin Family D Member 1	Protein Coding	6.92	DISEASES inferred ¹⁴
4	GP5	Glycoprotein V Platelet	Protein Coding	6.58	DISEASES inferred ¹⁴
5	INSM1	INSM Transcriptional Repressor 1	Protein Coding	6.52	DISEASES inferred ¹⁴
6	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	6.36	DISEASES inferred ¹⁴
7	KRT17	Keratin 17	Protein Coding	5.96	DISEASES inferred ¹⁴
8	GP6	Glycoprotein VI Platelet	Protein Coding	5.92	DISEASES inferred ¹⁴
9	TP53	Tumor Protein P53	Protein Coding	5.91	DISEASES inferred ¹⁴
10	MAPK8IP1	Mitogen-Activated Protein Kinase 8 Interacting Protein 1	Protein Coding	5.85	DISEASES inferred ¹⁴
11	ZNF582	Zinc Finger Protein 582	Protein Coding	5.68	DISEASES inferred ¹⁴
12	RUBCNL	Rubicon Like Autophagy Enhancer	Protein Coding	5.54	DISEASES inferred ¹⁴
13	FHIT	Fragile Histidine Triad Diadenosine Triphosphatase	Protein Coding	5.35	DISEASES inferred ¹⁴
14	MAL	Mal, T Cell Differentiation Protein	Protein Coding	5.32	DISEASES inferred ¹⁴
15	MIR518E	MicroRNA 518e	RNA Gene	5.2	DISEASES inferred ¹⁴
16	PAX1	Paired Box 1	Protein Coding	5.15	DISEASES inferred ¹⁴
17	PTPRN	Protein Tyrosine Phosphatase Receptor Type N	Protein Coding	5.06	DISEASES inferred ¹⁴
18	TMEM115	Transmembrane Protein 115	Protein Coding	5.06	DISEASES inferred ¹⁴
19	LGALS7B	Galectin 7B	Protein Coding	5.06	DISEASES inferred ¹⁴
20	LGALS7	Galectin 7	Protein Coding	5.05	DISEASES inferred ¹⁴
21	CD4	CD4 Molecule	Protein Coding	4.87	DISEASES inferred ¹⁴
22	RB1	RB Transcriptional Corepressor 1	Protein Coding	4.86	DISEASES inferred ¹⁴

Sources

Variations for Cervix Uteri Carcinoma in Situ

Sources

Expression for Cervix Uteri Carcinoma in Situ

Search GEO for disease gene expression data for Cervix Uteri Carcinoma in Situ.

Sources

Pathways for Cervix Uteri Carcinoma in Situ

Pathways related to Cervix Uteri Carcinoma in Situ according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	22q11.2 copy number variation syndrome ⁷⁴	11.45	TP53 SERPIND1 GP5
2	TP53 network ⁷⁴ Show member pathways Activation, translocation and oligomerization of BAX ⁶⁶	10.26	TP53 CDKN2A
3	Hypoxic and oxygen homeostasis regulation of HIF-1-alpha ⁶¹	9.85	TP53 CDKN2A

Sources

GO Terms for Cervix Uteri Carcinoma in Situ

Biological processes related to Cervix Uteri Carcinoma in Situ according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	apoptotic process	GO:0006915	9.65	TP53 MAL LGALS7B LGALS7 FHIT CDKN2A
2	heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules	GO:0007157	9.55	LGALS7B LGALS7 CADM1
3	hemostasis	GO:0007599	8.8	SERPIND1 GP6 GP5